Literature DB >> 12933923

A randomised controlled trial comparing rehabilitation against standard therapy in multiple sclerosis patients receiving intravenous steroid treatment.

J Craig1, C A Young, M Ennis, G Baker, M Boggild.   

Abstract

BACKGROUND: There is evidence to support both the use of intravenous methylprednisolone (IVMP) in multiple sclerosis (MS) relapse and physiotherapy in the management of MS, but no studies have investigated the combination of steroids and rehabilitation together.
OBJECTIVES: To evaluate the benefits of IVMP with planned, comprehensive multidisciplinary team (MDT) care compared to IVMP with standard care.
METHODS: In this randomised controlled trial, patients confirmed to have had a definite MS relapse severe enough to warrant IVMP (1 g daily for three days) were randomised to two groups. The control group was managed according to the standard ward routine; the treatment group received planned coordinated multidisciplinary team assessment and treatment. Baseline assessments, including demographics and Expanded Disability Status Scale (EDSS) were carried out on both groups. The primary outcome measures were Guy's Neurological Disability Scale (GNDS), and Amended Motor Club Assessment (AMCA). The secondary measures were the Barthel Index (BI), Human Activity Profile (HAP), and Short Form Item 36 Health Survey (SF-36). All measures have published data on reliability and validity. Measures were administered at one and three months.
RESULTS: Forty subjects, including 27 females, completed data collection. There were no significant differences between the two groups at baseline. Results showed statistically significant differences in GNDS (p = 0.03), AMCA (p = 0.03), HAPM (p < 0.01), HAPA (p = 0.02), and BI (p = 0.02) at three months in favour of planned MDT care.
CONCLUSION: This study indicates that combining steroids with planned MDT care is superior to administering them in a standard neurology or day ward setting. Further research is necessary in order to confirm this finding.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12933923      PMCID: PMC1738635          DOI: 10.1136/jnnp.74.9.1225

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  20 in total

1.  The management of multiple sclerosis: current and future therapies.

Authors:  V L Stevenson; A J Thompson
Journal:  Drugs Today (Barc)       Date:  1998-03       Impact factor: 2.245

2.  Prospective study of neurorehabilitation in multiple sclerosis.

Authors:  D Kidd; A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-04       Impact factor: 10.154

Review 3.  Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis.

Authors:  D E Goodkin
Journal:  West J Med       Date:  1994-09

4.  Maximum oxygen consumption and the ADAPT quality-of-life scale.

Authors:  D M Daughton; A J Fix; I Kass; C W Bell; K D Patil
Journal:  Arch Phys Med Rehabil       Date:  1982-12       Impact factor: 3.966

5.  Assessment of motor function in people with multiple sclerosis.

Authors:  L H De Souza; A Ashburn
Journal:  Physiother Res Int       Date:  1996

6.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.

Authors:  F D Lublin; S C Reingold
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

7.  Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis.

Authors:  D Barnes; R A Hughes; R W Morris; O Wade-Jones; P Brown; T Britton; D A Francis; G D Perkin; P Rudge; M Swash; H Katifi; S Farmer; J Frankel
Journal:  Lancet       Date:  1997-03-29       Impact factor: 79.321

8.  Use of corticosteroids in multiple sclerosis by consultant neurologists in the United Kingdom.

Authors:  H L Tremlett; D K Luscombe; C M Wiles
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-09       Impact factor: 10.154

9.  Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis.

Authors:  C M Wiles; R G Newcombe; K J Fuller; S Shaw; J Furnival-Doran; T P Pickersgill; A Morgan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-02       Impact factor: 10.154

10.  Inpatient rehabilitation in multiple sclerosis: do the benefits carry over into the community?

Authors:  J A Freeman; D W Langdon; J C Hobart; A J Thompson
Journal:  Neurology       Date:  1999-01-01       Impact factor: 9.910

View more
  22 in total

Review 1.  Rehabilitation interventions in multiple sclerosis: an overview.

Authors:  Serafin Beer; Fary Khan; Jürg Kesselring
Journal:  J Neurol       Date:  2012-07-08       Impact factor: 4.849

2.  Rehabilitation interventions for the management of multiple sclerosis relapse: a short scoping review.

Authors:  Miho Asano; Rebecca Raszewski; Marcia Finlayson
Journal:  Int J MS Care       Date:  2014

3.  Developing a wellness program for people with multiple sclerosis: description and initial results.

Authors:  Dennis L Hart; Ruth I Memoli; Brian Mason; Mark W Werneke
Journal:  Int J MS Care       Date:  2011

4.  [Multimodal complex treatment in advanced multiple sclerosis].

Authors:  M R Haupts; C Haug; D Seidel; H-P Hartung
Journal:  Nervenarzt       Date:  2013-06       Impact factor: 1.214

5.  Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report.

Authors:  Stephanie J Lee; Daniel Wolff; Carrie Kitko; John Koreth; Yoshihiro Inamoto; Madan Jagasia; Joseph Pidala; Attilio Olivieri; Paul J Martin; Donna Przepiorka; Iskra Pusic; Fiona Dignan; Sandra A Mitchell; Anita Lawitschka; David Jacobsohn; Anne M Hall; Mary E D Flowers; Kirk R Schultz; Georgia Vogelsang; Steven Pavletic
Journal:  Biol Blood Marrow Transplant       Date:  2015-03-19       Impact factor: 5.742

6.  Therapeutic management of severe relapses in multiple sclerosis.

Authors:  Carolyn Bevan; Jeffrey M Gelfand
Journal:  Curr Treat Options Neurol       Date:  2015-04       Impact factor: 3.598

7.  Management of acute exacerbations in multiple sclerosis.

Authors:  Daniel Ontaneda; Alex D Rae-Grant
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

8.  Barriers and Facilitators Related to Rehabilitation Stays in Multiple Sclerosis: A Qualitative Study.

Authors:  Caroline Bruun Helland; Trygve Holmøy; Pål Gulbrandsen
Journal:  Int J MS Care       Date:  2015 May-Jun

9.  Updates on clinically isolated syndrome and diagnostic criteria for multiple sclerosis.

Authors:  Jacqueline F Marcus; Emmanuelle L Waubant
Journal:  Neurohospitalist       Date:  2013-04

Review 10.  [New aspects of symptomatic MS treatment: Part 6 - cognitive dysfunction and rehabilitation].

Authors:  T Henze; W Feneberg; P Flachenecker; D Seidel; H Albrecht; M Starck; S G Meuth
Journal:  Nervenarzt       Date:  2018-04       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.